A Study of NX-1607 in Adults With Advanced Malignancies

Phase 1 Recruiting 345 enrolled Nurix Therapeutics, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

Timeline

Start: 2021-09-29
Primary completion: 2026-08-31
Completion: 2028-02-28

Publications

Wolf D, Baier G. IFNgamma Helps CBLB-Deficient CD8+ T Cells to Put Up Resistance to Tregs. Cancer Immunol Res. 2022 Apr 1;10(4):370. doi: 10.1158/2326-6066.CIR-22-0080.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NX-1607	Unknown	—	Oral
Subject	Paclitaxel	Small molecule	—	Intravenous

A Study of NX-1607 in Adults With Advanced Malignancies

Summary

Timeline

Publications

Drugs

Indications